Life Extension and Quality of Life Improvement for Humans

Abstract

The present invention discloses a system and method for preparing and delivering various health and longevity compositions. This invention is designed to improve the quality of life and lifespan of mammals. The compositions of the present invention are selected and designed for the purpose of efficiently delivering health and longevity enhancing therapies through oral supplementation; misting; nasal spray; intravenous, IM, and/or sub-cutaneous, injection; suppository; etc. A non-toxic therapeutic anabolic hormone replenishment is combined with rapamycin and cannabidiol. The three compounds work together to improve quality of life and healthy lifespan. Preferred additional included supplements may include metformin, growth hormone, and/or supplemented minerals. A preferred embodiment features low dose continuous supplementation, e.g., to be incorporated with a daily meal. The process of the present invention delivers an orally ingested substance, e.g., a snack, a human food supplement, an animal treat, etc., that contains the active compounds to be absorbed by the digestive system or delivered into the bloodstream.

Claims

1. A composition comprising an androgenic prohormone, rapamycin, and a cannabinoid compound that binds and stimulates a mammalian endocannabinoid receptor.

2. The composition of claim 1 further comprising [8 minerals], metformin, and growth hormone.

3. The composition of claim 1 wherein said endogenous endocannabinoid receptor is selected from the group consisting of: CB.sub.1, CB.sub.2, TRPV.sub.1, TRPV.sub.2, TRPV.sub.3, TRPV.sub.4, TRPA.sub.1, TRPM.sub.8, GPR.sub.119, GPR.sub.55, GPR.sub.118, GPR.sub.18 and non-human analogues thereto.

4. The composition of claim 1 wherein said cannabinoid compound comprises cannabidiol (CBD).

5. The composition of claim 3 wherein said cannabinoid compound also binds and stimulates at least one 5-HT receptor.

6. The composition of claim 1 further comprising an oil selected from the group consisting of: vegetable, rapeseed/canola, soy, corn, peppermint, lavender, sandalwood, bergamot, rose, chamomile, ylang-ylang, tea tree, myrcene/hops, jasmine, and lemon.

7. The composition of claim 1 further comprising nutmeg or nutmeg extract.

8. The composition of claim 1 present in an edible selected from the group consisting of: a toothpaste, a feed, a spritz, a small treat, a food formulation, a food supplement, a gummi, a prescription food product, a capsule, a pill, a reward, a spray, an ampule, a chewing gum, and a chew toy.

9. A gummi food comprising the composition of claim 1.

10. A chewing gum comprising the composition of claim 1.

11. The composition of claim 1 present in a format selected from the group consisting of: a liquid for spritzing into an oral or nasal opening, a liquid for misting, a liquid for sub cutaneous injection, a liquid for intra-venous injection, a liquid for intra-muscular injection, a lozenge, a buccal strip, and a suppository.

12. The composition of claim 1 present in a sterile format capable of presence in a syringe for injection.

13. The composition of claim 12, in a concentrated format designed for dilution prior to injection.

14. The composition of claim 11 present in a device comprising a mask or a tube that can deliver said liquid for misting into a nasal passage.

15. The composition of claim 1 further comprising at least one vitamin selected from the group consisting of: vitamin A carotenoids, B1 thiamin, B2 riboflavin, B3 niacin, B5 panthenic acid, B6, pyridoxal, B7 biotin, B9 folic acid/folate, B12 cobalamin, C ascorbate/ascorbic acid, D2 ergocalciferol, D3 cholcalciferol, K1 phylloquinone, K2 menaquinone, retinol, and retinyl ester.

16. The composition of claim 1 further comprising at least one mineral selected from the group consisting of: selenium, lithium, potassium, iron, phosphorus, zinc, manganese, and magnesium.

17. The composition of claim 15 further comprising at least one mineral selected from the group consisting of: selenium, lithium, potassium, iron, phosphorus, zinc, manganese, and magnesium.

18. The composition of claim 1 wherein said prohormone is selected from the group consisting of: DHEA, 7-keto DHEA and DHEA-S.

19. A method for providing a safe therapeutic composition to a mammal, said method comprising delivering to said mammal the composition of claim 1.

20. The method of claim 19 wherein said mammal is a feline.

21. The method of claim 19 wherein said mammal is a canine.

22. The method of claim 19, further comprising prior to said delivering: a purging comprising introducing into said mammal an activated charcoal substance at a dosage level between 500 mg/kg and 2000 mg/kg.

23. The method of claim 22 wherein said activated charcoal is introduced as an oral presentation in solid format or aqueous suspension format.

24. The method of claim 22 wherein said activated charcoal substance comprises KUARAY.

25. The method of claim 22 wherein said composition further comprises at least one vitamin selected from the group consisting of: vitamin A carotenoids, B1 thiamin, B2 riboflavin, B3 niacin, B5 panthenic acid, B6, pyridoxal, B7 biotin, B9 folic acid/folate, B12 cobalamin, C ascorbate/ascorbic acid, D2 ergocalciferol, D3 cholcalciferol, K1 phylloquinone, K2 menaquinone, retinol, and retinyl ester.

26. The method of claim 22 wherein said composition further comprises at least one mineral selected from the group consisting of: selenium, lithium, potassium, iron, phosphorus, zinc, manganese, and magnesium.

27. The method of claim 26 wherein said composition comprises: selenium, lithium, potassium, iron, phosphorus, zinc, manganese, and magnesium.

28. The method of claim 25 wherein said composition comprises: selenium, lithium, potassium, iron, phosphorus, zinc, manganese, and magnesium.

29. The method of claim 28 wherein said composition further comprises: vitamin A carotenoids, B1 thiamin, B2 riboflavin, B3 niacin, B5 panthenic acid, B6, pyridoxal, B7 biotin, B9 folic acid/folate, B12 cobalamin, C ascorbate/ascorbic acid, D2 ergocalciferol, D3 cholcalciferol, K1 phylloquinone, K2 menaquinone, retinol, and retinyl ester.

Description

EXAMPLE 1

[0082] Rapamycin and DHEA are prepared as gelatinous microspheres. The microspheric particles are ejected into a heated stream of CBD in a chamber where the microspheres are allowed to cool so that the CBD solidifies. The microspheres are collected from the chamber bottom and packaged into a selected food or supplement, e.g., a gummi of desired shape, a chewing gum, etc.

EXAMPLE 2

[0083] Rapamycin and DHEA are present in in a preparation of liquefied CBD. CBD can be liquefied by melting in a heated chamber. The mixture is atomized by spraying into an atomization chamber where an air current cools the stream and forms microsphere particles of CBD, rapamycin and DHEA. Alternatively, a solvent may dissolve with CBD to maintain a liquid preparation. The liquid with DHEA, rapamycin and CBD with solvent is atomized by spraying into a stream of heated gas, e.g., hot air or nitrogen. The atomization forms small droplets whose solvent is evaporated while passing through the stream of hot air. Microsphere particles are collected after passing through the evaporative stream.

[0084] Modification of these exemplary microsphere forming practices or other microsphere formation methods are capable of forming the preferred microspheric embodiments of the present invention.

EXAMPLE 3

[0085] A five year old canine (age dependent on the breed, the animal size, etc.) is evaluated at its annual visit. This visit includes a hormonal profile as well as questioning the dog owner about the animal's activities and general health. The veterinarian observes that is common at this age for this type of dog, testosterone levels are continuing to drop and that the dog might benefit from restoring circulating levels of testosterone or other androgenic hormone in the blood.

[0086] The veterinarian calculates a target testosterone level and suggests simple oral supplements of DHEA that can help the dog achieve these levels and to thereby pep up the dog to increase enjoyment of the dog and human associates. The prohormone is co-administered with longevity supporting rapamycin and a cannabinoid, e.g., cannabidiol, in a chicken flavored gummi. This format includes CBD that facilitates uptake of both other compounds in the gut and results in more predictable outcomes.

EXAMPLE 4

[0087] A seven-year-old canine (a 62 pound poodle) is evaluated at its annual visit. This visit includes a hormonal profile as well as questioning the dog owner about the animal's activities and general health. The veterinarian observes that is common at this age for this type of dog, testosterone levels are continuing to drop and that the dog might benefit from restoring circulating levels of testosterone or other androgenic hormones in the blood.

[0088] The veterinarian calculates a target stimulus level using DHEA as the deliverable androgen (prohormone) and suggests simple oral supplements of DHEA that can help the dog achieve these levels of hormone and to thereby restore activity levels in this poodle. The DHEA is delivered as multiple salmon flavored gummis that incorporate CBD encapsulated microspheres of rapamycin and DHEA. This improves interactions between the dog, the dog's owner, and the dog's family.

EXAMPLE 5

[0089] Customers find packets of life-enhancing gummi packets in their local pet store. Packets are available with gummis each containing 10 mg DHEA and 10 mg rapamycin. These may be given once daily to a mammal about 10 to 40 lbs., twice daily to a mammal about 20 to 80 lbs., more frequently to larger animals. Gummis may be cut or split for smaller or intermediate dosing.

[0090] For use as treats, e.g., for canine training, gummis with 0.5 mg of each substance may be available. These may be preferred for delivery to smaller animals.

EXAMPLE 6

[0091] A purging process is started at 8 am. This begins with offering water to the intended recipient of the active purging compound. For a 10 kg canine, 2 liver flavored treats each with 500 mg activated carbon are offered with ingestion confirmed. The canine is permitted free access to water, but no food until 11 am or later. In the evening, therapy commences with at least one gummi treat offered, prior to evening feeding normal food. Gummis of different formulation may be shape or color coded to allow the dispensing person to modify amounts and groups of compounds delivered in accordance with instructions or personal preferences. For example, a red gummi may include generally recommended amounts of: vitamin A carotenoids, B1 thiamin, B2 riboflavin, B3 niacin, B5 panthenic acid, B6, pyridoxal, B7 biotin, B9 folic acid/folate, B12 cobalamin, C ascorbate/ascorbic acid, D2 ergocalciferol, D3 cholcalciferol, K1 phylloquinone, K2 menaquinone, retinol, and/or retinyl ester. A green gummi may include: selenium, lithium, potassium, iron, phosphorus, zinc, manganese, and/or magnesium in conjunction with androgenic prohormone, rapamycin, and one or more cannabinoid compounds that bind and stimulate a mammalian endocannabinoid receptor. These are just examples. Other examples might be a teal gummi pill comprising: B1, B2, B3, B9, B12, Mg, and prohormone. Different formulations may be arbitrarily selected and distinguished for each gummi set to allow dosage personalized dosing. Though rare, when formulating the gummis attention should be paid to avoiding clumping or other undesired interactions between components.

Concluding Comments

[0092] Combined interventions involving two or more episodes of redirecting/rebalancing immune/allergy activity, balancing androgen levels in circulation, improving animal activity and outlook by optimizing mitochondrial activities will allow even more robust human-animal interaction and better outcomes for the participants. Mitochondrial activities may also be improved though supplementation with rapamycin and the CBD cannabinolic component in the composition of the invention. CBD has multiple effects, including, but not limited to: stimulating appetite, supporting mitochondrial activity, and enhancing intestinal uptake of the rapamycin and prohormone.

[0093] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Although for simplicity in drafting the claims below are drafted in a manner where each dependent claim specifically asserts dependent status with only a single claim, the reader is put on notice that for purpose of disclosure every claim that references a preceding claim also implicitly is understood to have alternate dependency to all claims ultimately depending from the same claim or claims.

[0094] Examples useful in practicing this invention may include a composition or using a composition that improves a non-human animal's well-being that may include, contain or comprise an orally or subcutaneously administrable substance having at least one dosage selected from the group consisting of: a mitochondrial booster, an androgen hormone and a prohormone, said dosage selected to optimize at least one physiologic function in a selected mammal. Examples may further feature a compound that has or supports cannabinolic activity perhaps with presence of an endocannabinoid substance. Activity of such compound may be effected through a G-protein coupled receptor such as CB.sub.1, CB.sub.2, TRPV.sub.1, TRPV.sub.2, TRPV.sub.3, TRPV.sub.4, TRPA.sub.1, TRPM.sub.8, GPR.sub.18, GPR.sub.55, GPR.sub.118, and/or GPR.sub.119. Anti-oxidant activity may be featured in one or more or the constituents formulated into the product composition.

[0095] Cannabinolic activity may reside in, for example, an endogenous mammalian cannabinoid, a phytocannabinoid and/or a synthetic cannabinoid including but not limited to: AEA, 2AG, PEA, OEA, LEA, URB597, URB937, AM374, ARN2508, BIA 10-2474, BMS-469908, CAY-10402, JNJ-245, JNJ-1661010, JNJ-28833155, JNJ-40413269, JNJ-42119779, JNJ-42165279, LY-2183240, Cannabidiol, MK-3168, MK-4409, MM-433593, OL-92, OL-135, PF-622, PF-750, PF-3845, PF-04457845, PF-04862853, RN-450, SA-47, SA-73, SSR-411298, ST-4068, TK-25, URB524, URB597 (KDS-4103), URB694, URB937, VER-156084, V-158866, AM3506, AM6701, CAY10435, CAY10499, IDFP, JJKK-048, JNJ-40355003, JNJ-5003, JW618, JW651, JZL184, JZL195, JZP-372A, KML29, MAFP, MJN110, ML30, N-arachidonoyl maleimide, OL-135, OL92, PF-04457845, SA-57, ST4070, URB880, URB937, indomethacin, MK-886, resveratrol, cis-resveratrol, aspirin, COX-1 inhibitor II, loganin, tenidap, SC560, FR 122047 hydrochloride, valeryl salicylate, FR122047 hydrate, ibuprofen, TFAP, 6-methoxy-2-naphthylacetic acid, meloxicam, APHS, etodolac, meloxicam, meloxicam sodium salt, N-(4-acetamidophenyl)indomethacin amide, N-(2-phenylethyl)indomethacin amide, N-(3-pyridyl)indomethacin amide, indomethacin heptyl ester, SC236, sulinac, sulindac sulfide, pravadoline, naproxen, naproxen sodium salt, meclofenamate sodium, ibuprofen, S-ibuprofen, piroxicam, ketoprofen, S-ketoprofen, R-ibuprofen, Ebselen, ETYA, diclofenac, diclofenac diethylamine, flurbiprofen, fexofenadine, Pterostilbene, Pterocarpus marsupium, 9,12-octadecadiynoic acid, Ketorolac (tromethamine salt), NO-indomethacin, S-flurbiprofen, sedanolide, green tea extract (e.g., epicatechin), licofelone, lornoxicam, rac ibuprofen-d3, ampirxicam, zaltoprofen, 7-(trifluoromethyl)1H-indole-2,3-dione, aceclofenac, acetylsalicylic acid-d4, S-ibuprofen lysinate, loxoprofen, CAY10589, ZLJ-6, isoicam, dipyrone, YS121, MEG (mercaptoethylguanidine), etc.

[0096] Such cannabinoids may be identified as members of a class such as: cannabigerol class, cannabichromene class, cannabicyclol class, .sup.8-tetrahydrocannabinol class, cannabieson class, cannabinol and cannabinodiol class, cannabitriol class and miscellaneous class.

[0097] Popular compositions used to practice the invention may include one or more cannabinoids selected from the group consisting of: CBGA, CBGAM, CBG, CBGM; CBGVA, CBGV, CBCA, CBC, CBCVA, CBCV, CBDA, CBD, CBDM, CBD-C4, CBDVA, CBDV, CBD-C1, THCA-A, THCA-B, 6a,10a-trans-6a,7,8,10a-tetra hydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, THC,) THCA-C4, THC-C4, THCVA, THCV, .sup.7-cis-isotetrahydrocannabivarin, THCA-C1, THC-C1, .sup.8-TCA, .sup.8-THC, CBL, CBLA, CBLV, CBEA-A, CBEA-B, CBE, CBNA, CBN, CBNM, CBN-C4, CBV, CBN-C2, CBN-C1), CBND, CBDV, CBT, 10-EHDT, 8,9-DHDT, CBTV, CBTVE, DCBF, CBF, CBCN, CBT, OTHC, cis-THC, 2H-iso-HHCV, CBR and triOH-THC.

[0098] Some practices of the invention can feature metabolism directive or accessory compounds or metabolically active compounds including, but not limited to: an FAAH inhibitor, R-WIN 55,212-2, a MAGL inhibitor, an EFA, oxytocin, -3 fatty acid, -6 fatty acid.

[0099] Some formulations may feature, for example, N-alkylamides, phytoalkanes, n-alkanes, N-acylethanolamines, flavonoids, curcuminoids, polyphenols, biphenyl neolignans, sesquiterpenes, N-Isobutylamides and/or p-hydroxyphenyl-O-arylcarba mates, whose carbon presence in the molecule of interest may be specific or in a range where each molecule comprises from 9 to 39 carbon atoms, for example, 9, 10, 11, 12, 13, 14,15,16,17, 18, 19, 20, 21, 22,23, 24, 25,26,27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 and/or 39 C/molecule.

[0100] Carbon chains may include branches with preferred compounds expected to feature 2-methyl-, 3-methyl-, and dimethyl attachments. Nonacosane, heptacosane, 2,6-dimethyltetra-decane, pentacosane, hexacosane, and hentriacontane are examples of useful carbon chains.

[0101] Phyto molecules are featured in some embodiments of this invention. A composition may thus feature parts or extracts, for example, of one of more sources derived from Echinacea, Echinacea purpurea, Echinacea angustifolia, curcurmin, Salvia divinorum, sage, lemon grass, hops, verbana, Cannabis, thyme, mango, Helichrysum umbraculigerum, liverwort, cacao, ginger, tumeric, Curcuma longa, Magnolia officinalis, Norway spruce, basil, Myristica fragrans, cloves, Sciadopitys verticillata, oregano, cinnamon, black pepper, hemp, rosemary, flax, Elettaria repens, etc.

[0102] Phyto- or phyto-mimic compounds/molecules may include but are not limited to: abinene, -pinene, 4,8-dimethyl-1,7-nonadien-4-ol, 2-hydroxy-4-methyl-valeric, acid, methyl, ester, octanal, O-cymene, eucalyptol, -phellandrene, cis-sabinene, hydroxide, myrcenol, terpinen-4-ol, -terpineol, -thujene, -terpinene, trans--ocimene, carveol, -citral, guanidine, geraniol, bornyl, acetate, -pinene, thymol, geranic, acid, methyl, ester, -terpinyl, acetate, d-limonene, eugenol, geranyl, acetate, dihydrocarvyl, acetate, -ylangene, cis-dodec-5-enal, 3-phenyl-2-propenoic, acid, methyl, ester, -elemene, c, vanillin, epoxy--terpenyl, acetate, butanoic, acid, 2-methyl-, 3,7-dimethyl-2,6-octadienyl, ester, 1-methyl-4-(1-acetoxy-1-methylethyl)-cyclohex-2-enol, 1,2,3,4,4a,5,6,8a-octahydro-4a,8-dimethyl-2-(1-methylethenyl)-, [2r-(2,4a,8a)]-naphthalene, p-mentha-1(7), 8-dien-2-ol, -muurolene, hydroxy--terpenyl, acetate, nerolidol, geranyl, bromide, ()--panasinsen, pyrocatechol, -elemene, 9,10-dehydro-isolongifolene, -calacorene, cis-verbenol, acetic, acid, 1-methyl-1-(4-methyl-5-oxo-cyclohex-3-enyl)ethyl, ester, alloaromadendrene, z,z-2,6-dimethyl-3,5,7-octatriene-2-ol, 4-epi-cubedol, 2-oxabicyclo[2.2.2]octan-6-ol, 1,3,3-trimethyl-acetate, patchoulane, farnesol, caryophyllene, oxide, cis-lanceol, ledene, oxide-(ii), farnesol, acetate, 6-epi-shyobunol, falcarinol, phytol, aromadendrene, oxide-(2), heptacosane, longipinene, epoxide, hentriacontane, decamethyl-cyclopentasiloxane, geranyl, isobutyr, hexamethyl-cyclotrisiloxane, 1-docosene, tetratetracontane, dodecamethyl-cyclohexasiloxane, etc.

[0103] Supplemental components used to modify or to improve more rudimentary formulations or compositions may comprise, but are not limited to: -caryophyllene, a -caryophyllene oxide, salvinorin A, myrcene, perrottetinenic acid, apigenin, quercetin, cannflavin A, cannflavin B, -sitosterol, vitexin, isovitexin, kaempferol, luteolin, orientin, a gingerol, capsaicin, curcumin, demethoxycurcumin, bisdemethoxycurcumin, cyclocurcumin, trans-resveratrol, diferuloylmethane, trans-arachidins, trans-piceatannol, isoprenylated trans-resveratrol derivatives, sciadonic acid magnolol, honokiol, malyngamide B, (+) sabinene, () sabinene, lsobutylamide, dodeca-2E,4E-dienoic acid isobutylamide, dodeca-2E,4E,8Z,10Z-tetraenoic acid alkylamide, 1-[(2E,4E,8Z)-tetradecatrienoyl] piperidine, -caryophyllene, ajulemic acid, etc .

[0104] Compositions are not limited to classic medicament shapes or formats. For example, a gel, a powder, a toy, a liquid, a food supplement, a moist food, a dry food, a small treat, a solidified matrix, etc., may be used for delivery. A 3-D printer may be applied to control dosing of the featured components, e.g., a hormone or prohormone, Delayed-release shaped constructs, a chewable toy-shaped substance, e.g., a doggie bone, a dinosaur, a cat, a mouse, a squirrel, a rodent, a ring, a fist, a bow, a ball, etc. One or more formats may feature a plurality of packagings, wherein at least a first packaging contains active ingredient for admixing to at least a second package contents.